Bristol Myers Squibb Net Income
| BMY Stock | USD 60.74 0.88 1.47% |
As of the 16th of February 2026, Bristol Myers shows the Risk Adjusted Performance of 0.1912, mean deviation of 1.36, and Downside Deviation of 1.42. Bristol Myers Squibb technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Bristol Myers Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 3.3232 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 7.1 B | 7.4 B | |
| Net Income Applicable To Common Shares | 7.1 B | 7.4 B | |
| Net Income From Continuing Ops | 7.1 B | 7.4 B | |
| Net Income Per Share | 3.46 | 3.63 | |
| Net Income Per E B T | 0.76 | 0.66 |
Bristol | Net Income | Build AI portfolio with Bristol Stock |
The evolution of Net Income for Bristol Myers Squibb provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Bristol Myers compares to historical norms and industry peers.
Latest Bristol Myers' Net Income Growth Pattern
Below is the plot of the Net Income of Bristol Myers Squibb over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Bristol Myers Squibb financial statement analysis. It represents the amount of money remaining after all of Bristol Myers Squibb operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Bristol Myers' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bristol Myers' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 7.05 B | 10 Years Trend |
|
Net Income |
| Timeline |
Bristol Net Income Regression Statistics
| Arithmetic Mean | 2,620,802,941 | |
| Geometric Mean | 3,796,617,783 | |
| Coefficient Of Variation | 188.58 | |
| Mean Deviation | 3,381,461,592 | |
| Median | 3,439,000,000 | |
| Standard Deviation | 4,942,365,179 | |
| Sample Variance | 24426973.6T | |
| Range | 17B | |
| R-Value | 0.11 | |
| Mean Square Error | 25723405.1T | |
| R-Squared | 0.01 | |
| Significance | 0.67 | |
| Slope | 110,485,784 | |
| Total Sum of Squares | 390831577T |
Bristol Net Income History
Other Fundumenentals of Bristol Myers Squibb
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Bristol Myers Net Income component correlations
Bristol Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Bristol Myers is extremely important. It helps to project a fair market value of Bristol Stock properly, considering its historical fundamentals such as Net Income. Since Bristol Myers' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bristol Myers' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bristol Myers' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. Projected growth potential of Bristol fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Bristol Myers assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 13.921 | Dividend Share 2.49 | Earnings Share 3.46 | Revenue Per Share | Quarterly Revenue Growth 0.013 |
Bristol Myers Squibb's market price often diverges from its book value, the accounting figure shown on Bristol's balance sheet. Smart investors calculate Bristol Myers' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Bristol Myers' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Bristol Myers' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bristol Myers should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Bristol Myers 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Bristol Myers' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Bristol Myers.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Bristol Myers on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Bristol Myers Squibb or generate 0.0% return on investment in Bristol Myers over 90 days. Bristol Myers is related to or competes with GlaxoSmithKline PLC, HCA Holdings, Sanofi ADR, Cigna Corp, Elevance Health, CVS Health, and McKesson. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwi... More
Bristol Myers Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Bristol Myers' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Bristol Myers Squibb upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.42 | |||
| Information Ratio | 0.1913 | |||
| Maximum Drawdown | 8.0 | |||
| Value At Risk | (1.98) | |||
| Potential Upside | 3.59 |
Bristol Myers Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bristol Myers' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Bristol Myers' standard deviation. In reality, there are many statistical measures that can use Bristol Myers historical prices to predict the future Bristol Myers' volatility.| Risk Adjusted Performance | 0.1912 | |||
| Jensen Alpha | 0.3652 | |||
| Total Risk Alpha | 0.2708 | |||
| Sortino Ratio | 0.2425 | |||
| Treynor Ratio | 0.6164 |
Bristol Myers February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1912 | |||
| Market Risk Adjusted Performance | 0.6264 | |||
| Mean Deviation | 1.36 | |||
| Semi Deviation | 1.05 | |||
| Downside Deviation | 1.42 | |||
| Coefficient Of Variation | 434.55 | |||
| Standard Deviation | 1.8 | |||
| Variance | 3.25 | |||
| Information Ratio | 0.1913 | |||
| Jensen Alpha | 0.3652 | |||
| Total Risk Alpha | 0.2708 | |||
| Sortino Ratio | 0.2425 | |||
| Treynor Ratio | 0.6164 | |||
| Maximum Drawdown | 8.0 | |||
| Value At Risk | (1.98) | |||
| Potential Upside | 3.59 | |||
| Downside Variance | 2.02 | |||
| Semi Variance | 1.1 | |||
| Expected Short fall | (1.66) | |||
| Skewness | 0.4564 | |||
| Kurtosis | 0.5205 |
Bristol Myers Squibb Backtested Returns
Bristol Myers appears to be very steady, given 3 months investment horizon. Bristol Myers Squibb secures Sharpe Ratio (or Efficiency) of 0.26, which signifies that the company had a 0.26 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Bristol Myers Squibb, which you can use to evaluate the volatility of the firm. Please makes use of Bristol Myers' Risk Adjusted Performance of 0.1912, downside deviation of 1.42, and Mean Deviation of 1.36 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Bristol Myers holds a performance score of 20. The firm shows a Beta (market volatility) of 0.66, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Bristol Myers' returns are expected to increase less than the market. However, during the bear market, the loss of holding Bristol Myers is expected to be smaller as well. Please check Bristol Myers' sortino ratio, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether Bristol Myers' price patterns will revert.
Auto-correlation | 0.58 |
Modest predictability
Bristol Myers Squibb has modest predictability. Overlapping area represents the amount of predictability between Bristol Myers time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Bristol Myers Squibb price movement. The serial correlation of 0.58 indicates that roughly 58.0% of current Bristol Myers price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.58 | |
| Spearman Rank Test | 0.47 | |
| Residual Average | 0.0 | |
| Price Variance | 6.31 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Bristol Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Bristol Myers Squibb reported net income of 7.05 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is significantly lower than that of the firm.
Bristol Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bristol Myers' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bristol Myers could also be used in its relative valuation, which is a method of valuing Bristol Myers by comparing valuation metrics of similar companies.Bristol Myers is currently under evaluation in net income category among its peers.
Bristol Myers ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bristol Myers' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bristol Myers' managers, analysts, and investors.Environmental | Governance | Social |
Bristol Myers Institutional Holders
Institutional Holdings refers to the ownership stake in Bristol Myers that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Bristol Myers' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bristol Myers' value.| Shares | Ubs Asset Mgmt Americas Inc | 2025-06-30 | 25.2 M | Northern Trust Corp | 2025-06-30 | 24.9 M | Primecap Management Company | 2025-06-30 | 22.9 M | Independent Franchise Partners Llp | 2025-06-30 | 21 M | Bank Of New York Mellon Corp | 2025-06-30 | 20.9 M | Amvescap Plc. | 2025-06-30 | 18.3 M | Bank Of America Corp | 2025-06-30 | 17.9 M | Dimensional Fund Advisors, Inc. | 2025-06-30 | 16.3 M | Fmr Inc | 2025-06-30 | 16.2 M | Vanguard Group Inc | 2025-06-30 | 194.9 M | Blackrock Inc | 2025-06-30 | 172.2 M |
Bristol Fundamentals
| Return On Equity | 0.4 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.28 % | ||||
| Current Valuation | 160.16 B | ||||
| Shares Outstanding | 2.04 B | ||||
| Shares Owned By Insiders | 0.10 % | ||||
| Shares Owned By Institutions | 83.17 % | ||||
| Number Of Shares Shorted | 29.89 M | ||||
| Price To Earning | 24.88 X | ||||
| Price To Book | 6.70 X | ||||
| Price To Sales | 2.57 X | ||||
| Revenue | 48.19 B | ||||
| Gross Profit | 35 B | ||||
| EBITDA | 14.54 B | ||||
| Net Income | 7.05 B | ||||
| Cash And Equivalents | 10.21 B | ||||
| Cash Per Share | 6.21 X | ||||
| Total Debt | 2.26 B | ||||
| Debt To Equity | 1.32 % | ||||
| Current Ratio | 1.42 X | ||||
| Book Value Per Share | 9.07 X | ||||
| Cash Flow From Operations | 14.16 B | ||||
| Short Ratio | 2.42 X | ||||
| Earnings Per Share | 3.46 X | ||||
| Price To Earnings To Growth | 2.26 X | ||||
| Target Price | 59.91 | ||||
| Number Of Employees | 34.1 K | ||||
| Beta | 0.3 | ||||
| Market Capitalization | 123.7 B | ||||
| Total Asset | 90.04 B | ||||
| Retained Earnings | 16.9 B | ||||
| Working Capital | 5.97 B | ||||
| Current Asset | 10.41 B | ||||
| Current Liabilities | 8.02 B | ||||
| Annual Yield | 0.04 % | ||||
| Five Year Return | 2.96 % | ||||
| Net Asset | 90.04 B | ||||
| Last Dividend Paid | 2.49 |
About Bristol Myers Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bristol Myers Squibb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bristol Myers using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bristol Myers Squibb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bristol Stock Analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.